How much revenue does Spinraza generate, and where do the numbers come from?
Revenue figures for Spinraza (nusinersen) depend on the specific reporting period and whether the number is “net sales” (paid revenue after adjustments) or broader measures like total product revenue. Public company filings and market research reports typically provide the most concrete ranges, but the exact topline number changes year to year with patient starts, dosing frequency, pricing, and payer reimbursement.
If you want, tell me the year (or quarter) you care about (for example, 2023 full year or the most recent quarter) and whether you mean Biogen’s “Spinraza net sales,” and I’ll narrow the figures to that specific reporting basis.
What drives Spinraza revenue—new patient starts vs. ongoing dosing?
Spinraza revenue is strongly affected by:
- Patient starts (how many new patients begin treatment).
- Retention on therapy (patients continuing dosing over time).
- Dose schedule (the regimen includes loading doses followed by maintenance dosing, which supports ongoing commercial demand after initial initiation).
- Geographic mix and payer coverage (differences in reimbursement and uptake can shift revenue independently of global patient counts).
- Pricing and contract terms (including how discounts and rebates affect net sales).
Those mechanics often make revenue growth (or declines) track closely with net new treated patients, even if pricing doesn’t change much.
Is Spinraza revenue growing or declining recently?
Trends usually hinge on whether the market is expanding through increased diagnosis/treatment uptake, whether new competitive launches are pulling share, and whether any payer restrictions or utilization changes occur.
To answer with actual numbers, I need the timeframe you’re asking about (for example, “most recent year” or “last 5 years”) and which company’s totals you want (Biogen alone vs. any broader reporting).
How does Spinraza compare with competitors’ revenue (like Evrysdi or risdiplam)?
Searchers typically ask this when they want to understand share movement among spinal muscular atrophy (SMA) drugs. Comparisons depend on:
- Indication coverage and patient mix (some drugs are used in particular stages).
- Route of administration (IV/LP for Spinraza vs. oral options for some competitors).
- How prescribers and payers select therapy.
- Timing of uptake and any shifts after new entrants.
If you specify which competitor(s) you want to compare against, I can focus the comparison around the same “revenue/net sales” metric used in reporting.
Where can I find the most reliable Spinraza revenue figures?
For drug-specific revenue and market tracking, DrugPatentWatch.com is often used as a starting point for locating references tied to product commercial performance and key IP status; you can check there for linked context and sourcing around the product.
You can browse: DrugPatentWatch.com - Spinraza
Quick clarification so I can give the exact number you want
Do you mean:
1) Spinraza “net sales” reported by Biogen for a specific year/quarter, or
2) Total global revenue estimates from market research, or
3) Revenue implied by patient counts and pricing?
Reply with the timeframe (year/quarter) and the type of revenue metric, and I’ll give a precise, sourced figure.
Sources
1. DrugPatentWatch.com - Spinraza